Novo Nordisk reiterated last week, during a presentation to investors and analysts, the importance of its new investigational obesity therapy semaglutide for its future. Novo recently completed a Phase II clinical trial with semaglutide vs Saxenda vs Placebo, enrolling 1,000…
Saxenda
Novo Nordisk today announced that EMA CHMP adopted a positive opinion on updating the label for Saxenda in Europe. The authorization is based on results from the LEADER clinical trial, assessing the long-term effects of Victoza (liraglutide up to 1.8…